Год
2023
-
Mesoblast Cell Therapy Gets RMAT Designation for Chronic Low Back Pain
-
EMA Clarifies Its Policy on Biosimilar Interchangeability
-
Janssen’s Nipocalimab Shines in HDFN Trial
-
Rocket Pharmaceuticals Gets RMAT Designation for Danon Disease Gene Therapy
-
Sage and Biogen’s Depression Drug Candidate Gets Priority Review
-
Roche’s Crovalimab Trial Reaches Endpoints in Patients With PNH
-
Aldeyra’s reproxalap for dry eye disease accepted by FDA
-
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial
-
Mesoblast Resubmits BLA for Remestemcel-L
-
Eisai’s New Alzheimer’s Drug Leqembi Hits the U.S. Market